Social Media Ideas for Advancis

<![CDATA[Advancements in Oral Treatments for IBD]]>

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Sunshine Guojian Releases 2026 Interim Report:

Innovation-driven, Steady Advancement

Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 developmen...

<![CDATA[MedAdvisor Solutions Rebrands as Adheris ]]>

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study.

Pfizer-backed Priovant wins FDA approval for lead asset

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline...

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment...

Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product

With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory...